Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 11/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | PYGL | P06737 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27228996 | 0.86 | P2RX7 (0.37) | P2RX7CHRNA7CNR2 | |
| SCHEMBL23100734 | 0.86 | P2RX7 (0.37) | P2RX7CHRNA7CNR2 | |
| SCHEMBL10276776 | 0.86 | P2RX7 (0.37) | P2RX7CHRNA7CNR2 | |
| SCHEMBL25297558 | 0.81 | P2RX7 (0.47) | P2RX7CHRNA7 | |
| SCHEMBL15909256 | 0.81 | P2RX7 (0.47) | P2RX7CHRNA7 | |
| SCHEMBL25297559 | 0.81 | P2RX7 (0.47) | P2RX7CHRNA7 | |
| SCHEMBL9998573 | 0.78 | PYGL (0.36) | P2RX7MAPK1CHRNA7PYGLCYP2C9 | |
| SCHEMBL20660045 | 0.78 | CPN1 (0.44) | P2RX7 | |
| SCHEMBL18492741 | 0.78 | P2RX7 (0.36) | P2RX7 | |
| SCHEMBL8136541 | 0.77 | PYGL (0.41) | PYGLCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865726-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20120178715-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2011029027-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178715-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MTOR, RICTOR, EIF4EBP1 | P2RX7 591/4885MAPK1 221/4885CHRNA7 4726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.